Zanubrutinib

泽布替尼

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameZanubrutinib
Drug Alias NameZanubrutinb赞布替尼Brukinsa百悦泽BGB-3111
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Primary mediastinal B cell lymphomaCentral Nervous System Lymphoma +[24] 
Global Approved IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaLymphoma, Mantle-CellLeukemia, Lymphocytic, Chronic, B-Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2019/11/14
Country/TerritoryCzechiaBelgiumBulgaria +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMedison PharmaBeigene Singapore Pte LtdBeigene Ireland Ltd +[21] 
Inactive CompaniesBeigene (Usa) IncThe University Of Texas MD Anderson Cancer Center
Active IndicationsPrimary mediastinal B cell lymphomaCentral Nervous System LymphomaImmunoglobulin G4-Related Disease +[19] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Lung DiseasesHepatic Insufficiency +[5] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG